Short Interest in Revelation Biosciences, Inc. (NASDAQ:REVB) Declines By 61.9%

Revelation Biosciences, Inc. (NASDAQ:REVB) was the target of a significant decline in short interest in the month of March. As of March 15th, there was short interest totalling 23,500 shares, a decline of 61.9% from the February 28th total of 61,700 shares. Based on an average daily volume of 239,900 shares, the short-interest ratio is currently 0.1 days. Approximately 2.6% of the company’s shares are sold short.

Revelation Biosciences Stock Performance

Revelation Biosciences stock traded down $0.06 during trading on Friday, hitting $2.70. The company’s stock had a trading volume of 9,098 shares, compared to its average volume of 113,667. The stock’s fifty day moving average is $3.84 and its 200 day moving average is $8.58. Revelation Biosciences has a 1-year low of $2.36 and a 1-year high of $60.80. The stock has a market capitalization of $2.44 million, a price-to-earnings ratio of -0.01 and a beta of 0.17.

About Revelation Biosciences

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.